Q-omics provides the consensus-scored NUDT12 profile across patient tissues and cancer cell-line models. NUDT12 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NUDT12 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, NUDT12 protein abundance shows 23,001 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where NUDT12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUDT12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUDT12 survival associations across molecular data types. NUDT12 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUDT12 RNA expression–survival associations across cancer types. High NUDT12 expression shows unfavorable associations in UVM and STAD, but favorable associations in KIRC, ACC, MESO and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NUDT12 RNA expression.
This table summarizes NUDT12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NUDT12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUDT12 shows lower tumor expression in COAD, LUSC, KIRP, UCEC, KIRC and HNSC. The COAD box plot shows higher NUDT12 RNA expression in normal versus tumor tissue (log2 FC = −1.087, t-test p < 0.001).
This table shows molecular features associated with NUDT12 in patient tissues and cancer cell lines. In patient samples, NUDT12 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NUDT12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
